Efferent Labs

Investor Relations

Efferent Labs® is a preclinical-stage biotechnology company focused on the discovery, development, and commercialization of cell-based preclinical research products.
We are poised to change healthcare and drug discovery by reducing time and cost to bring medications to market.

Our patented CytoComm® platform provides information never before available to clinical researchers by allowing for real-time cell-based preclinical research utilizing stable reporter cell lines to evaluate molecular interactions (e.g. protein expression changes or gene activation) in vivo.

Our technology revolutionizes the preclinical testing market by providing real-time in vivo molecular information resulting in a reduction of early stage testing expenses.

Investor Portal

https://vimeo.com/954559348

Our transformative technology platform will dramatically reduce R&D costs.

get in touch

The Benefits

Our Board

Dante Pennacchia
CHAIRMAN – EFFERENT LABS
PRESIDENT – MAXUALIZE™
Bradford Berk, MD, PhD
DIRECTOR – EFFERENT LABS
DIRECTOR – ROCHESTER NEURORESTORATIVE INSTITUTE
Efrain Rivera, DM, MBA, JD
DIRECTOR – EFFERENT LABS
SENIOR VICE PRESIDENT, CFO, AND TREASURER – PAYCHEX
Efrain Rivera, DM, MBA, JD
DIRECTOR – EFFERENT LABS
SENIOR VICE PRESIDENT, CFO, AND TREASURER – PAYCHEX
W.K. (Bill) Rader
EXECUTIVE VICE CHAIRMAN, AND CEO
W.K. (Bill) Rader
EXECUTIVE VICE CHAIRMAN, AND CEO
Spencer Z. Rosero, MD
DIRECTOR, CHIEF MEDICAL OFFICER